Evidence map›Paper›PMID 41358161›Full record

ArticleiScience2025

Phosphatidylserine receptors TIM-1 and AXL mediate tick-borne Powassan virus entry.

Maria Daskou, Anne K Zaiss, Arjit Vijey Jeyachandran, Kari-Ann Takano, Ryan L Kan, Ramya Paravastu, Ephrem Gerald, Nivedha Satheeshkumar, Jennifer Rios-Rodriguez, Brandy Russell and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Maria DaskouDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
Anne K ZaissDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
Arjit Vijey JeyachandranDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
Kari-Ann TakanoDepartment of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Ryan L KanDepartment of Biological Chemistry, University of California, Los Angeles, Los Angeles, CA, USA.
Ramya ParavastuDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
Ephrem GeraldDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
Nivedha SatheeshkumarDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
Jennifer Rios-RodriguezDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
Brandy RussellCenters for Disease Control and Prevention (CDC), Division of Vector-Borne Diseases, Fort Collins, CO, USA.
Aaron C BraultCenters for Disease Control and Prevention (CDC), Division of Vector-Borne Diseases, Fort Collins, CO, USA.
Aparna BhaduriDepartment of Biological Chemistry, University of California, Los Angeles, Los Angeles, CA, USA.
Gustavo GarciaDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
Kouki MorizonoDepartment of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Vaithilingaraja ArumugaswamiDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.

Funding

Interplay between AMPK and Hippo Signaling Regulates Ocular Antiviral Response to Zika virus infectionR01EY032149 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Vaithilingaraja Arumugaswami, Ashok Kumar · 2021 to 2026
$2.8M
Defining Ocular Monkey Pox Pathogenic MechanismsR01EY036572 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Vaithilingaraja Arumugaswami, Ashok Kumar · 2025 to 2026
$1.4M
NEI NIH HHS R01 EY032149NEI NIH HHS R01 EY036572
6 · The paper itself

Abstract

Powassan virus (POWV) is an emerging tick-borne neurotropic human pathogen. Currently, there are no approved medications or vaccines available. The goal of this study is to investigate the receptor usage for POWV, which can be a potential therapeutic target. For this purpose, we used cell culture-based models including neuronal cells, 293T cells stably expressing different viral entry receptors, and induced pluripotent stem cell (iPSC)-derived cortical organoids, as well as

Indexed as

Molecular biologyPharmacologyVirology

Identifiers

PMID41358161
PMCPMC12677074

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.